Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals has got patent 4,546,454 entitled, Antisense Oligonucleotides that Inhibit Expression of HIF-1,' from the Japanese Patent Office (JPO).
Subscribe to our email newsletter
The Japan patent covers Rexahn’s preclinical compound RX-0047 and a method of inhibiting the expression of HIF-1 in human cells or tissues.
HIF-1, a human protein is involved in angiogenesis, cancer cell survival, radiation resistance and cancer metastasis.
RX-0047 has demonstrated the ability to inhibit the expression of HIF-1 and also to induce toxicity in several cancer cell lines.
Rexahn Pharma said the preclinical studies to date have demonstrated potent anti-proliferative, anti-tumor and anti-metastatic activities.
Rexahn Pharma president Rick Soni said obtaining this additional patent coverage for RX-0047 in the large pharmaceutical market of Japan is another step forward for the development of this compound, and helps strengthen our overall global intellectual property position.